American journal of surgery · 2025
Cost analysis in thyroid cancer clinical trials: Toward value-based oncology care.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rogers James L, Henostroza Sebastian, Fahey Adam, Solórzano Carmen C
Аннотация
BACKGROUND: Clinical trials are crucial in advancing novel therapies for thyroid cancer. Given the increased cost of modern healthcare, cost considerations in clinical trials are important yet remain under-reported.
METHODS: A search of ClinicalTrials.gov identified thyroid cancer studies including cost in the trial description or as an outcome. Data collected included trial information, cost outcomes, and cost-effectiveness analyses.
RESULTS: Among 46 thyroid cancer-focused clinical trials, only 28 (60.8 %) mentioned cost in any capacity, of which 21 (75 %) included cost outcomes and 7 (25 %) included cost-effectiveness analyses. Overall, cost was a primary outcome in 1 (2.2 %) trial, secondary outcome in 20 (43.5 %) trials, and exploratory outcome in 7 (15.2 %) trials.
CONCLUSION: The inclusion of cost analysis in thyroid cancer clinical trials is limited. Given rising cost pressures in modern healthcare systems, the low prevalence of cost endpoints and cost-effectiveness analyses underscores the need for increased awareness and investment in this domain.
METHODS: A search of ClinicalTrials.gov identified thyroid cancer studies including cost in the trial description or as an outcome. Data collected included trial information, cost outcomes, and cost-effectiveness analyses.
RESULTS: Among 46 thyroid cancer-focused clinical trials, only 28 (60.8 %) mentioned cost in any capacity, of which 21 (75 %) included cost outcomes and 7 (25 %) included cost-effectiveness analyses. Overall, cost was a primary outcome in 1 (2.2 %) trial, secondary outcome in 20 (43.5 %) trials, and exploratory outcome in 7 (15.2 %) trials.
CONCLUSION: The inclusion of cost analysis in thyroid cancer clinical trials is limited. Given rising cost pressures in modern healthcare systems, the low prevalence of cost endpoints and cost-effectiveness analyses underscores the need for increased awareness and investment in this domain.